Sanofi plans to enter Cheplapharm's capital by transferring 20 medicines and 3 sites
Sanofi would enter Cheplapharm's capital at 26.4% in exchange for the transfer of a selection of mature medicines and three industrial sites. The transaction extends a collaboration initiated between the two groups in 2014.
Twenty medicines and three sites transferred to Cheplapharm
Sanofi and Cheplapharm announced on September 14, 2026 their intention to create a strategic partnership. Under this framework, Cheplapharm would take over from Sanofi a selection of 20 mature medicines and three industrial sites worldwide.
In return, Sanofi would take a 26.4% stake in Cheplapharm's capital. The transferred medicines include Lovenox/Clexane (enoxaparin), with the exception of the United States.
Cheplapharm, a family-owned company based in Germany, is presented in the press release as specialized in mature generic medicines and number one in France in this segment.
Three sites involved in Hungary, Singapore and France
Three production sites would be transferred to Cheplapharm: Csanyikvölgy in Hungary (approximately 400 employees), Jurong in Singapore (approximately 100 employees) and Ploërmel in France (approximately 65 employees). According to the press release, the teams would continue their activities with the maintenance of employment and collective agreements.
The two groups indicate their intention to work closely together to ensure the transition and continuity of supplies.
Transfer extended until the third quarter of 2027
The commercial transfer of the medicine portfolio is expected to begin in the first quarter of 2027, followed by that of the sites, subject to employee information and consultation procedures, regulatory approvals and customary closing conditions. The transaction is expected to be fully completed in the third quarter of 2027.
Sanofi clarifies that the proposed transaction should have no impact on its financial forecasts for 2026. Additional financial details are expected to be communicated at a later stage.
